N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial is a research paper published in Contemporary Clinical Trials (2022). On theSindex it has a DataRank of 0.742. It has been cited 22 times, with 21 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0.272
From 17 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 21 citers.
U.S. Department of Defense
Grant: MS200179
Atara Biotherapeutics
Genentech
National Multiple Sclerosis Society
Bayer Fund
Biogen
Alexion Pharmaceuticals
Teva Pharmaceutical Industries
Novartis
National Institutes of Health
Sanofi Genzyme
Roche
Patient-Centered Outcomes Research Institute
MeSH Terms
Keywords